Moreover, the results of IHC indicated that Ki67 expression increased in the LUCAT1-overexpressing tumor tissues compared to the control group following osimertinib treatment, while no significant difference was observed between the two groups without the drug (Fig. 3H, I). This evidence concerns the gene LUCAT1 and neoplasm.